Axicabtagene Ciloleucel Outperforms Conventional First-Line Therapy
In a groundbreaking comparative study published in BMC Cancer, researchers have provided compelling evidence demonstrating the superiority of axicabtagene ciloleucel (axi-cel), a novel CAR T-cell...
















